[go: up one dir, main page]

PE20080373A1 - Formulaciones de alisquireno e hidroclorotiazida - Google Patents

Formulaciones de alisquireno e hidroclorotiazida

Info

Publication number
PE20080373A1
PE20080373A1 PE2007000804A PE2007000804A PE20080373A1 PE 20080373 A1 PE20080373 A1 PE 20080373A1 PE 2007000804 A PE2007000804 A PE 2007000804A PE 2007000804 A PE2007000804 A PE 2007000804A PE 20080373 A1 PE20080373 A1 PE 20080373A1
Authority
PE
Peru
Prior art keywords
hydrochlorothiazide
weight
amount
alisquirene
metoxy
Prior art date
Application number
PE2007000804A
Other languages
English (en)
Inventor
Matthias Willmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080373(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080373A1 publication Critical patent/PE20080373A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION ORAL SOLIDA QUE COMPRENDE a) UN INHIBIDOR DE RENINA TAL COMO ALISQUIRENO (2(S),4(S),5(S),7(S)-N-(3-AMINO-2,2-DIMETIL-3-OXO-PROPIL)-2,7-DI-(1-METIL-ETIL)-4-HIDROXI-5-AMINO-8-[4-METOXI-3-(3-METOXI-PROPOXI)-FENIL]OCTANAMIDA) O UNA SAL DEL MISMO, b) HIDROCLOROTIAZIDA (HCTZ) Y c) UN RELLENO HIDROFILICO TAL COMO DEXTRINA, DEXTROSA, LACTOSA, MANITOL, SORBITOL, ENTRE OTROS; DONDE EL ALISQUIRENO SE ENCUENTRA EN UNA CANTIDAD DE ENTRE 25% AL 47% EN PESO EN BASE AL PESO TOTAL DE LA FORMULACION, LA HIDROCLOROTIAZIDA SE ENCUENTRA EN UNA CANTIDAD DE ENTRE 0,5% A 10% EN PESO Y EL COMPONENTE c) SE ENCUENTRA EN UNA CANTIDAD DE ENTRE EL 3% A 30% EN PESO. TAMBIEN PUEDE CONTENER UN DESINTEGRANTE TAL COMO POLIVINILPIRROLIDONA; UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO, TALCO, ENTRE OTROS; UN DERRAPANTE TAL COMO TRISILICATO DE MAGNESIO, SILICE COLOIDAL, CELULOSA EN POLVO, ENTRE OTROS.
PE2007000804A 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida PE20080373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
PE20080373A1 true PE20080373A1 (es) 2008-06-06

Family

ID=36803824

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000804A PE20080373A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida
PE2012000368A PE20120990A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000368A PE20120990A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida

Country Status (26)

Country Link
US (1) US8618172B2 (es)
EP (3) EP3391878A1 (es)
JP (1) JP5362556B2 (es)
KR (1) KR101442272B1 (es)
CN (1) CN101472566A (es)
AR (1) AR061565A1 (es)
AU (1) AU2007263261B2 (es)
BR (1) BRPI0713338A2 (es)
CA (1) CA2654872A1 (es)
CL (1) CL2007001837A1 (es)
EC (1) ECSP088986A (es)
ES (1) ES2704979T3 (es)
GB (1) GB0612540D0 (es)
GT (1) GT200800297A (es)
IL (1) IL195425A (es)
MA (1) MA30527B1 (es)
MX (1) MX2008016533A (es)
MY (1) MY146779A (es)
NO (1) NO20090262L (es)
NZ (1) NZ572937A (es)
PE (2) PE20080373A1 (es)
RU (1) RU2491058C2 (es)
TN (1) TNSN08528A1 (es)
TW (1) TWI457137B (es)
WO (1) WO2007147596A1 (es)
ZA (1) ZA200809773B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548553A1 (en) * 2007-09-28 2013-01-23 Novartis AG Galenical formulations of aliskiren
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
US20100093603A1 (en) * 2008-07-17 2010-04-15 Kenneth Baker Use of organic compounds
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
WO2014152296A1 (en) * 2013-03-15 2014-09-25 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
DK1507558T3 (da) * 2002-05-17 2011-12-05 Novartis Pharma Ag Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
TW200538154A (en) * 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds
AR048431A1 (es) 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
CA2605771A1 (en) * 2005-04-27 2006-11-02 Novartis Ag Methods of treating atherosclerosis
WO2007048027A2 (en) * 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent

Also Published As

Publication number Publication date
US20090203679A1 (en) 2009-08-13
RU2491058C2 (ru) 2013-08-27
EP2034968A1 (en) 2009-03-18
CN101472566A (zh) 2009-07-01
AR061565A1 (es) 2008-09-03
MY146779A (en) 2012-09-28
TW200808358A (en) 2008-02-16
EP2034968B1 (en) 2018-10-31
PE20120990A1 (es) 2012-08-16
CA2654872A1 (en) 2007-12-27
EP2311439A1 (en) 2011-04-20
TNSN08528A1 (en) 2010-04-14
CL2007001837A1 (es) 2008-06-13
JP2009541239A (ja) 2009-11-26
BRPI0713338A2 (pt) 2012-03-06
TWI457137B (zh) 2014-10-21
ECSP088986A (es) 2009-01-30
NO20090262L (no) 2009-01-19
AU2007263261B2 (en) 2011-07-14
GB0612540D0 (en) 2006-08-02
KR101442272B1 (ko) 2014-09-22
IL195425A (en) 2014-01-30
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
GT200800297A (es) 2009-03-09
AU2007263261A1 (en) 2007-12-27
NZ572937A (en) 2011-11-25
IL195425A0 (en) 2009-08-03
EP3391878A1 (en) 2018-10-24
WO2007147596A1 (en) 2007-12-27
ZA200809773B (en) 2009-11-25
KR20090021353A (ko) 2009-03-03
US8618172B2 (en) 2013-12-31
RU2009101971A (ru) 2010-07-27
ES2704979T3 (es) 2019-03-21
JP5362556B2 (ja) 2013-12-11

Similar Documents

Publication Publication Date Title
PE20080373A1 (es) Formulaciones de alisquireno e hidroclorotiazida
ES2524771T3 (es) Composiciones farmacéuticas que comprenden levetiracetam y procedimientos para su preparación
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
CR9232A (es) Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas
PE20090882A1 (es) Preparacion solida que comprende alogliptina y clorhidrato de metformina
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
CR9425A (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CR20110340A (es) Compuestos purina
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
TN2010000038A1 (en) Organic compounds
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PE20060602A1 (es) Derivados de heteroaril acil pirrolidina como inhibidores del virus de la hepatitis c (hcv)
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
CL2009000896A1 (es) Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades.

Legal Events

Date Code Title Description
FC Refusal